5 Best Immunology Stocks to Buy According to Hedge Funds

4. Moderna, Inc. (NASDAQ:MRNA)

Number of Hedge Fund Holders: 52

Moderna, Inc. (NASDAQ:MRNA) is among the best immunology stocks to invest in.

TheFly reported earlier this month, on May 4, that UBS increased its price objective on MRNA to $45 from $36 while continuing to hold a Neutral stance on the stock. The firm pointed to several upcoming pipeline developments that could influence investor sentiment if the company delivers favorable clinical results across its programs.

More recently, on May 21, Moderna, Inc. (NASDAQ:MRNA) disclosed that its investigational mRNA influenza vaccine will undergo evaluation by an FDA advisory committee on June 18 ahead of the agency’s August 5 regulatory decision deadline. The scheduled review marks a significant step in the vaccine’s approval process and reflects renewed emphasis on external scientific assessment during regulatory evaluations.

The advisory panel meeting is expected to examine clinical evidence supporting the vaccine candidate’s safety and effectiveness before the FDA determines whether to authorize the product. The development also drew attention as advisory committee reviews had become less frequent in recent years for certain vaccine applications. Investors and industry observers are closely monitoring the outcome of the meeting, as positive feedback from the panel could strengthen confidence in Moderna’s broader respiratory vaccine pipeline and support future commercial opportunities beyond its COVID-19 franchise.

Moderna, Inc. (NASDAQ:MRNA) is a biotechnology company specializing in mRNA-based therapies and vaccines. Founded in 2010 and headquartered in Cambridge, Massachusetts, it develops treatments for infectious diseases, cancer, rare diseases, and autoimmune disorders.